Pharvaris N.V. (PHVS) NASDAQ
28.98
-0.12(-0.41%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
28.98
-0.12(-0.41%)
Currency In USD
Address
J.H. Oortweg 21
Leiden, 2333 CH
Netherlands (Kingdom of the)
Phone
31 71 203 6410
Website
Sector
Healthcare
Industry
Biotechnology
Employees
108
First IPO Date
February 05, 2021
| Name | Title | Pay | Year Born |
| Berndt Axel Edvard Modig | Co-Founder, Chief Executive Officer & Executive Director | 810,629 | 1959 |
| David W. Nassif | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | 0 | 1954 |
| Maryann Cimino | Director of Corporate Relations | 0 | N/A |
| Wim Souverijns | Chief Commercial Officer | 0 | 1971 |
| Anna Nijdam | Head of Strategic Finance & Principal Accounting Officer | 0 | 1981 |
| Annick Deschoolmeester | Chief Human Resources Officer | 0 | 1973 |
| Anne Lesage | Chief Early Development Officer | 0 | 1961 |
| Stefan Abele | Chief Technology Operations Officer | 0 | 1970 |
| Peng Lu | Chief Medical Officer | 0 | 1978 |
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.